Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15525678 | 0.95 | BRD4 (0.41) | HSP90AA1HSP90AB1LIPEKCNH2HRH3 | |
| SCHEMBL30985923 | 0.93 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1LIPEKCNH2HRH3 | |
| SCHEMBL15525925 | 0.92 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1 | |
| SCHEMBL15525661 | 0.90 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1LIPEKCNH2HRH3 | |
| SCHEMBL15525676 | 0.89 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1 | |
| SCHEMBL15526019 | 0.89 | BRD4 (0.48) | HSP90AA1HSP90AB1 | |
| SCHEMBL22547843 | 0.88 | BRD4 (0.42) | HSP90AA1HSP90AB1LIPE | |
| SCHEMBL22548022 | 0.88 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1LIPE | |
| SCHEMBL28343992 | 0.87 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1 | |
| SCHEMBL22541155 | 0.87 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110559446-A | Targeted therapeutics | 马德里加尔制药公司 | 2019-12-13 | — | — | CN | disclosed |
| US-9597343-B2 | Targeted therapeutics | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3131586-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3129064-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015143004-A9 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-3035938-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015143004-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015134464-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150139905-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| CN-104470941-A | Targeted therapeutics | SYNTA PHARMACEUTICALS CORP | 2015-03-25 | — | — | CN | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2838909-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013158644-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150139905-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885LIPE 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.